Ensign Peak Advisors Inc Acquires 1,300 Shares of Novavax, Inc. (NASDAQ:NVAX)

Ensign Peak Advisors Inc raised its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 3.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,900 shares of the biopharmaceutical company’s stock after acquiring an additional 1,300 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Novavax were worth $568,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Banque Cantonale Vaudoise grew its stake in shares of Novavax by 500.0% during the 2nd quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 2,500 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Novavax by 26.9% in the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,036 shares during the last quarter. Swedbank AB acquired a new stake in shares of Novavax in the 1st quarter valued at approximately $26,000. Signaturefd LLC boosted its holdings in shares of Novavax by 214.5% in the 2nd quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 3,874 shares during the last quarter. Finally, Herr Investment Group LLC acquired a new stake in shares of Novavax in the 1st quarter valued at approximately $48,000. 53.04% of the stock is owned by institutional investors.

Novavax Price Performance

NVAX stock opened at $13.30 on Friday. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -4.20 and a beta of 2.04. The business’s fifty day moving average price is $12.76 and its two-hundred day moving average price is $10.91. Novavax, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $23.86.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.82 by ($0.83). The business had revenue of $415.50 million during the quarter, compared to analysts’ expectations of $458.57 million. During the same quarter last year, the firm earned $0.58 EPS. Novavax’s revenue for the quarter was down 2.1% on a year-over-year basis. Research analysts expect that Novavax, Inc. will post -1.04 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on NVAX. B. Riley reissued a “buy” rating and issued a $23.00 price objective (down previously from $25.00) on shares of Novavax in a report on Monday, August 12th. JPMorgan Chase & Co. raised their price target on Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a report on Monday, August 12th. Finally, Bank of America raised their price target on Novavax from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Friday, June 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $15.80.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.